MTCH1 and cervical cancer: Consistent with the synergistic inhibition of the growth of cervical cancer by targeting MTCH1 in combination with sorafenib treatment,[62] we found that MTCH2 knockout synergistically facilitates the antitumor activity of sorafenib in CRC liver metastasis, indicating that the MTCH2 knockout and sorafenib had effects partially on distinct pathways.